Providence Portland Medical Center
Our goal is to define novel pathways that can be manipulated either alone, or in combination with vaccination, to enhance the T cell response in patients with cancer and chronic viral infection. More »
More »
Brendan D. Curti, M.D., focuses on developing biotherapies to treat malignancies of the prostate, kidney and bladder. More »
More »
More »
The Integrated Therapies Laboratory is a collaborative research effort between Michael J. Gough, Ph.D., and Marka R. Crittenden, M.D., Ph.D. It encompasses their overlapping research interest into the ability of cytotoxic therapy to provide large-scale cancer cell death in vivo, while modifying the profile of immune cells within the tumor. More »
More »
The main focus of the Laboratory of Basic Immunology, led by Andrew D. Weinberg, Ph.D., is to understand T cell activation during disease states. We have explored ways to manipulate the fate of antigen-specific T cells to enhance tumor-specific memory in hosts with cancer or downregulate antigen-specific responses in autoimmune disease. More »
The long-term goal of the Laboratory of Cancer Immunobiology, led by Hong-Ming Hu, Ph.D., is to understand how the immune system senses tumor cells and develop effective cancer vaccines and immunotherapy strategies. More »
The Laboratory of Immunologic Monitoring measures patients' immune responses to different anti-cancer immunotherapy interventions, such as experimental cancer vaccines, to assess their effectiveness. More »
The Laboratory of Molecular and Tumor Immunology, led by Bernard A. Fox, Ph.D., hypothesizes that a primary reason for the failure of past tumor vaccine strategies is that the magnitude of the antitumor immune response is insufficient to mediate tumor regression. One answer to this is to create a lymphopenic host, reconstitute that host with lymphocytes and then inoculate with a tumor vaccine. More »
The long-term goal of the laboratory, led by Emmanuel T. Akporiaye, Ph.D., is to better understand the events in the tumor microenvironment that interfere with the immune response and to develop immunologic interventions to overcome them. More »
Providence Thoracic Oncology Program emphasizes a multidisciplinary approach to cancer management. Our clinical trials program offers a broad array of innovative clinical research, including studies of new surgical techniques, radiation, chemotherapy, targeted therapy and immunotherapy agents, and tissue banking. Rachel E. Sanborn, M.D., specializes in thoracic oncology and clinical research, studying new agents or combinations in the treatment of lung cancer, mesothelioma and other thoracic tumors. More »
More »
More »
See a list of open research studies by cancer type. More »
Patients can access the latest heart and vascular therapies, which are currently available only through clinical research studies. More »
The goal of the laboratory, led by William L. Redmond, Ph.D., is to determine the molecular mechanisms by which tumors induce immune suppression. Ultimately, understanding how tumors escape destruction by the immune system will guide the development of novel anti-tumor therapies. More »
The Earle A. Chiles Research Institute (EACRI) is a multidisciplinary center devoted to health care study. Since 1960, research activities at the Providence Portland Medical Center-based EACRI have resulted in life-saving and cost-saving treatment for patients with heart disease, cancer, diabetes and infectious diseases. More »
Purpose of study: To determine if Nuedexta exerts a palliative effect on speech, swallowing and salivation in patients with ALS.
Principal Investigator: Dr. Kimberly Goslin
Contact: Providence ALS Research Nurse at 503 962-1171
Sponsor: ALS Association (ALSA) and the Northeast ALS Consortium (NEALS) More »
More »